TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Enrolling
The purpose of this study is to:
* Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events
* Evaluate the efficacy of nucresiran compared to placebo on additional assessments of CV events and/or death
* Evaluate the efficacy of nucresiran compared to placebo on patient-reported health status and health-related quality of life
Trial at a Glance
- Trial ID
- ALN-TTRSC04-003
- Condition
- Transthyretin Amyloidosis With Cardiomyopathy
- Drug/Treatment
- Sterile Normal Saline (0.9% NaCl), Placebo, Nucresiran
- Does this trial use a placebo?
- Yes
- Trial Type
- Interventional
- Number of Participants
- 1750 participants
- Trial dates
- 2025-07-02 - 2032-11-30
For more information:NCT07052903
Who can participate?
AGE
18 to 85 Years
SEX
All
ACCEPTS HEALTHY VOLUNTEERS?
No
Inquire about a clinical trial
Contact Alnylam directly with any questions about our clinical trials.
Inquire about a clinical trial
Contact Alnylam directly with any questions
about our clinical trials.
about our clinical trials.
